1-12 of 12
Richard Dillon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3 -mutant AML after contemporary induction therapy

Clinical Trials & Observations
Jad Othman, Angela Hwang, Maximillian Brodermann, Islam Abdallah, Kayleigh McCloskey, Paolo Gallipoli, Georgina Clarke, Raymond Dang, Jennifer Vidler, Pramila Krishnamurthy, Faisal Basheer, Anne-Louise Latif, Renuka Palanicawandar, Tom Taylor, Asra Khan, Victoria Campbell, Francesca Hogan, Alex Kanellopoulos, Kathryn Fleming, Angela Collins, Chris Dalley, Justin Loke, Scott Marshall, David Taussig, Sreetharan Munisamy, Eleana Loizou, Heba Yassin, Mike Dennis, Rui Zhao, Edward Belsham, Duncan Murray, Nicole Fowler, Jenny O'Nions, Anjum Khan, Rob Sellar, Richard Dillon
Journal: Blood Advances
Blood Adv (2024) 8 (21): 5590–5597.
https://doi.org/10.1182/bloodadvances.2024014017
Published: 2024
Includes: Supplemental data
Journal Articles

Venetoclax–based low intensity therapy in molecular failure of NPM1 -mutated AML

Clinical Trials & Observations
Carlos Jimenez-Chillon, Jad Othman, David Taussig, Carlos Jimenez-Vicente, Alexandra Martinez-Roca, Ing Soo Tiong, Manish Jain, James Aries, Seda Cakmak, Steven Knapper, Daniel Tuyet Kristensen, Vidhya Murthy, Joy Zacharoula Galani, Charlotte Kallmeyer, Loretta Ngu, David Veale, Simon Bolam, Nina Orfali, Anne Parker, Cara Manson, Jane Parker, Thomas Erblich, Deborah Richardson, Katya Mokretar, Nicola Potter, Ulrik Malthe Overgaard, Anne Stidsholt Roug, Andrew H. Wei, Jordi Esteve, Martin Jädersten, Nigel Russell, Richard Dillon
Journal: Blood Advances
Blood Adv (2024) 8 (2): 343–352.
https://doi.org/10.1182/bloodadvances.2023011106
Published: 2024
Includes: Supplemental data
Journal Articles

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Clinical Trials & Observations
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, Steve Knapper, Sylvie D. Freeman, Leona M. Batten, Joanna Canham, Emily L. Hinson, Julie Wych, Sophie Betteridge, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4539–4549.
https://doi.org/10.1182/bloodadvances.2023010276
Published: 2023
Includes: Supplemental data
Journal Articles

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study

Clinical Trials & Observations
Stuart Scott, Richard Dillon, Christian Thiede, Sadia Sadiq, Ashley Cartwright, Hazel J. Clouston, Debbie Travis, Katya Mokretar, Nicola Potter, Andrew Chantry, Liam Whitby
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3686–3694.
https://doi.org/10.1182/bloodadvances.2022009379
Published: 2023
Includes: Supplemental data
Journal Articles

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS

Justin Loke, Nicholas McCarthy, Aimee Jackson, Shamyla Siddique, Andrea Hodgkinson, John Mason, Charles Crawley, Maria Gilleece, Andrew Peniket, Rachel Protheroe, Rahuman Salim, Eleni Tholouli, Keith Wilson, Georgia Andrew, Richard Dillon, Naeem Khan, Victoria Potter, Pramila Krishnamurthy, Charles Craddock, Sylvie Freeman
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3666–3676.
https://doi.org/10.1182/bloodadvances.2022009493
Published: 2023
Includes: Supplemental data
Journal Articles

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation

Harry J. Iland, Nigel Russell, Richard Dillon, Andre C. Schuh, Aditya Tedjaseputra, Andrew Wei, Asim Khwaja, Steven Knapper, Steven W. Lane, John Reynolds, Mary Frances McMullin, Annalise Martin, Peter Tan, David C. Taussig, Anny Wong, John Taper, Christina Fraga, Richard Kelly, Kiran Tawana, Priyanka Mehta, Alain Mina, Jessica K. Altman, Ingolf Mølle, Sudhir Tauro, Eleni Tholouli
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2580–2585.
https://doi.org/10.1182/bloodadvances.2022007126
Published: 2023
Includes: Supplemental data
Journal Articles

T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy

Claire Horgan, Khushnuma Mullanfiroze, Archana Rauthan, Katharine Patrick, Naeem Akram Butt, Oana Mirci-Danicar, Olya O’Connor, Caroline Furness, Akshay Deshpande, Sarah Lawson, Valerie Broderick, Pamela Evans, Brenda Gibson, Wing Roberts, Salah Ali, Sevasti Galani, Amy A. Kirkwood, Jelena Jovanovic, Richard Dillon, Paul Virgo, Beki James, Kanchan Rao, Persis J. Amrolia, Robert F. Wynn
Journal: Blood Advances
Blood Adv (2023) 7 (10): 2155–2165.
https://doi.org/10.1182/bloodadvances.2022009253
Published: 2023
Journal Articles

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders

Patrick Harrington, Ashwini Kurshan, Marc Delord, Thomas Lechmere, Amna Sheikh, Jamie Saunders, Chandan Saha, Richard Dillon, Claire Woodley, Susan Asirvatham, Natalia Curto-Garcia, Jennifer O’ Sullivan, Shahram Kordasti, Deepti Radia, Donal McLornan, Michael H. Malim, Claire Harrison, Katie J. Doores, Hugues de Lavallade
Journal: Blood Advances
Blood Adv (2023) 7 (10): 1954–1957.
https://doi.org/10.1182/bloodadvances.2022008375
Published: 2023
Includes: Supplemental data
Journal Articles

Clinical impact of NPM1 -mutant molecular persistence after chemotherapy for acute myeloid leukemia

Ing S. Tiong, Richard Dillon, Adam Ivey, James A. Kuzich, Nisha Thiagarajah, Kirsty M. Sharplin, Chung Hoow Kok, Aditya Tedjaseputra, James P. Rowland, Carolyn S. Grove, Emad Abro, Jake Shortt, Devendra K. Hiwase, Ashish Bajel, Nicola E. Potter, Matthew L. Smith, Claire J. Hemmaway, Abin Thomas, Amanda F. Gilkes, Nigel H. Russell, Andrew H. Wei
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5107–5111.
https://doi.org/10.1182/bloodadvances.2021005455
Published: 2021
Includes: Supplemental data
Journal Articles

Patients with triple-negative, JAK2 V617F- and CALR -mutated essential thrombocythemia share a unique gene expression signature

Samah Alimam, William Villiers, Richard Dillon, Michael Simpson, Manohursingh Runglall, Alexander Smith, Prodromos Chatzikyriakou, Paul Lavender, Anju Kanda, Ken Mills, Beatriz Bellosillo Paricio, James Kaufman-Cook, Sophie Ord, Shahram Kordasti, Deepti Radia, Claire Woodley, Yvonne Francis, Ghulam Mufti, Donal P. McLornan, Claire N. Harrison
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1059–1068.
https://doi.org/10.1182/bloodadvances.2020003172
Published: 2021
Includes: Supplemental data
Journal Articles

Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma

Barbara Ottolini, Nadia Nawaz, Christopher S. Trethewey, Sami Mamand, Rebecca L. Allchin, Richard Dillon, Paul A. Fields, Matthew J. Ahearne, Simon D. Wagner
Journal: Blood Advances
Blood Adv (2020) 4 (11): 2392–2403.
https://doi.org/10.1182/bloodadvances.2019001075
Published: 2020
Includes: Supplemental data
Journal Articles

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Paul Milne, Charlotte Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie D. Freeman, Kathleen Gallagher, Amy Publicover, Sarah Pagan, Helen Marr, Gail L. Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark Levis, Steven Knapper, Matthew Collin
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3052–3061.
https://doi.org/10.1182/bloodadvances.2019000197
Published: 2019
Includes: Supplemental data